Cepheid (CPHD) Posts Q4 Profits Ex-Items

Cepheid (NASDAQ: CPHD) reported Q4 EPS of $0.11, ex-items, $0.24 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $131.5 million versus the consensus estimate of $125.34 million.

"2014 was a very strong year for Cepheid, marked by record revenue, record GeneXpert® System placements, and a record number of additions to our Xpert test menu, in addition to solid progress in further improving our gross margin," said John Bishop, Cepheid's Chairman and Chief Executive Officer. "While we are targeting Commercial Clinical growth of 20% or higher in 2015, we continue to invest strategically and aggressively in further test menu expansion, geographic expansion, and market segment expansion, which we believe sets the stage for a prolonged period of growth ahead for Cepheid."

For earnings history and earnings-related data on Cepheid (CPHD) click here.

You May Also Be Interested In

• Top AI Semiconductor Stocks According to Stifel Analysis
• Amrize Ltd (AMRZ) PT Lowered to $40 at DA Davidson as FY26 Guidance 'at Risk'
• HIMS jumps 7% on peptide tailwind but Citi sees 17% downside from here